Rochester,NY 9/1/2009 9:28:48 PM
Schering-Plough Corporation SGP, Ends Clarinex Fight With Orchid Over Patents
Schering-Plough Corporation
Schering-Plough has settled a patent lawsuit against Orchid Chemicals & Pharmaceuticals and Orgenus Pharma over their proposed generic versions of solid oral dosage formulations of the allergy drug Clarinex.
The agreement will allow Chennai, India-based Orchid, which had alleged that the ’274 and ’223 patents covering the drug are invalid, to introduce a generic version of Clarinex (desloratadine) orally disintegrating tablets Jan. 1, 2012, and Clarinex 5-mg tablets July 1, 2012, Schering-Plough says in a statement. Orgenus is a U.S. subsidiary of Orchid.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
